How Sun Pharma is avoiding a tariff hit by agreeing to MFN pricing for US Medicaid
3 sources·Updated September 2, 2026
Covered by 3 sources
- The Hindu Health·2d agoSun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
Read at The Hindu Health → - Hindustan Times India·2d agoIndia's largest drugmaker Sun Pharma inks deal with US govt to supply cheaper medicines to Americans
The Mumbai-based pharma company will provide 'Most Favoured Nation' pricing to state Medicaid programmes in the United States.
Read at Hindustan Times India → - Business Today IN·3d agoHow Sun Pharma is avoiding a tariff hit by agreeing to MFN pricing for US Medicaid
Sun Pharma’s latest US agreement comes as the drugmaker expands its presence in innovative medicines, with America accounting for 27% of its global revenue and the $11.75 billion Organon acquisition reinforcing its long-term bet on the market.
Read at Business Today IN →
